Clinical Observation Of Paclitaxel Or Docetaxel Plus Cisplatin With5-fluorouracil Plus Cisplatin For Advanced Esophageal Cancer: A Meta-analysis

Objective: To evaluate the efficacy and safety of Paclitaxel or Docetaxel plusCisplatin with5–Fluorouracil plus Cisplatin(PF) for The treatment of patients withadvanced Esophageal cancer in china.Methods: Collect randomized controlled trials(RCT) about the treatment of advanced Esophageal cancer,by RevMan5.0.2software tocomplete Meta analysis.Results: A total of twenty-one RCTs involving1318patientswere included. The results of meta-analyses showed that without radiotherapy theexperimental group was more effective than the control group (RR=1.63,95%CI[1.44,1.85], P<0.01).The major adverse effects were neutropenia,Theexperimental was higher than the control (RR=1.44,95%CI[1.04,2.00], P=0.03); therewas significant difference between the radiotherapy combined with paclitaxel andplatinum and radiotherapy combined with PF group,either in RR,but no difference in theone year survival rate(RR=1.18,95%CI[1.03,1.35], P=0.02; RR=1.13,95%CI[0.97,1.31],P=0.11), But the difference was obvious of the lowers of thrombocytopenia(RR=1.63,95%CI[1.06,2.51], P=0.03).Conclusion: In treatment of advanced esophagealcancer,Paclitaxel plus platinum trentment are more effective than the PF,The majoradverse effects were neutropenia but combined with radiotherapy didn’t improvelong-term survival trends except can improve the RR,but the experimental groupsignifieantly inereased thrombocytopenia toxieity.Based on the chinese studies, for thequality restrictions of the included studies, more double blind RCT with high quality arerequired to further assess the effects.